CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport

(2010) Jean-Yves Wach et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

(2010) J. J. Wright   CLINICAL CANCER RESEARCH

Anguinomycins and Derivatives: Total Syntheses, Modeling, and Biological Evaluation of the Inhibition of Nucleocytoplasmic Transport

(2010) Simone Bonazzi et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

p53-based Cancer Therapy

(2010) D. P. Lane et al.   Cold Spring Harbor Perspectives in Biology

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

(2009) J. G. Turner et al.   CANCER RESEARCH

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

(2009) S. C. Mutka et al.   CANCER RESEARCH

A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer

(2009) J.-Y. Yang et al.   CLINICAL CANCER RESEARCH

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

Heterocyclic Compounds That Inhibit Rev-RRE Function and Human Immunodeficiency Virus Type 1 Replication

(2008) D. Shuck-Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure–activity relationship and mechanism of action

(2008) Tine Van Neck et al.   BIOORGANIC & MEDICINAL CHEMISTRY

CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer

(2008) Joel Turner et al.   CURRENT MEDICINAL CHEMISTRY

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation

(2008) R. K. Kancha et al.   HAEMATOLOGICA

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

(2008) Anwesha Dey et al.   NATURE REVIEWS DRUG DISCOVERY